Introduction
Measurement of the QoL is becoming increasingly important in clinical patient management. The World Health Organization (WHO) has expanded and codified the definition of health to include mental and social well-being, making it multidimensional. This has permitted us, in the last few decades, to develop QoL concepts and adopt different instruments for multidimensional evaluation of health (1) . The main reason for the rapid development of QoL measures in healthcare is the growing recognition of the importance of understanding the impact of healthcare interventions on the patient's QoL rather than merely treating their bodies (2) . Further, physicians have always intended to find out and understand how their patients feel. This is particularly important for patients affected by neurodegenerative disorders, either disabling or life threatening (3) . Evidence that measuring QoL provides a better evaluation of these latter conditions is presented in the recent literature. The aim of this review was to assess the role and importance of principal QoL scales in neurodegenerative and demyelinating disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), which account for a significant and increasing proportion of morbidity and mortality in the developed world. Largely as a result of increased life expectancy and changing population demographics, neurodegenerative disorders are becoming increasingly common (4) . Evaluation of QoL has acquired increasing importance in neurodegenerative diseases. Treatment of neurodegenerative diseases places a substantial medical, social, and psychological burden on patients and their families and profoundly affects the QoL of all persons involved. QoL refers to people's emotional, social, and physical well-being and their ability to function in daily life (5) . QoL measures attempt to directly evaluate the impact of neurodegenerative diseases or interventions on people's ability to function in life. Besides this global conceptualisation of QoL, there is a growing field of research on QoL measures focussed on the measurement of health-related QoL (HRQoL). Instruments aimed at measuring the patient's health status outlook enable us to quantify the loss of QoL caused by disease and the improvement that can be achieved by interventions (6) . Disease-specific measurements are devised to assess the impact of a specific disease across a spectrum of important domains of life. They evaluate the relevant domains for a specific disease. Currently, most of the tools consider the physical conditions, the psychological comfort, and the level of activity, whereas a few consider, for example, the social sphere (7) . For some tools an external evaluator is needed, for example, the physician, whereas in the majority of cases the questionnaires are answered by the patient himself. In patients suffering from neurodegenerative diseases (such as AD, PD, MS, and ALS), the evaluation of QoL could involve significant difficulties because of the relative unreliability of subjective assessment in the early stages of disease, as well as because of language barriers that make it impossible to obtain information about the patient's experience during later stages. During the course of the disease, every patient could reach a stage of cognitive decline in which any type of introspective evaluation of memory might be possible (8) . Perez et al. argue that specific instruments tend to be more responsive to changes and more sensitive to discriminating the range of impairment because of their focus on the most relevant aspects of the QoL for the problems assessed. For all these reasons, it is necessary to study other fields on the basis of carefully selected specific measures of QoL chosen as being of particular importance to patients and to the hypotheses being tested. However, a critical analysis of the properties of the growing range of generic and disease-specific measures is necessary to guide and direct researchers and clinicians towards the most appropriate measures in terms of reliability, validity, and sensitivity to change instruments used in measuring the QoL (does it really measure what it is supposed to measure?); reliable (does it give the same measurement after repeated administrations in stable patients?); sensitive (does it reflect clinically meaningful differences in the QoL across the broad spectrum of clinical conditions?); and responsive (does it detect changes when the patient's condition changes?). In Italy at present some translated and validated tools are being increasingly used in the neurological field (9) . The aim of this work review was to assess the role of the principal QoL scales as a state-of-the-art measuring tool for assessing the QoL of patients suffering from neurodegenerative diseases.
Methods/tools
Alzheimer's Disease Questionnaire
The dementia QoL Instrument (DQoL) was specifically designed for self-assessment of QoL in AD patients with dementia using the Mini Mental State Examination (MMSE) > 12, without the intervention of the caregiver. The original work included a structured interview consisting of 96 items that investigated the characteristics of patients and their experiences of living with dementia. The interview included questions on the following: functional status, basic and advanced activities of daily living, mobility, physical well-being, social interaction skills, aesthetic awareness, and perception of the QoL. The instrument takes , 10 min to administer. The validation work has led to the current version, which consists of 56 items divided into five domains (aesthetics, positive affection, negative affection, self-esteem, feeling of belonging) (10) (see Table 1 ). Item-stems were made as simple as possible and a five-point visual scale was used to present multiple choice responses to patients. All points on the response scale are associated with verbal descriptors. Screening questions ensure that patients understand the instructions on the questionnaire and the response format for the scale. In a sample of 99 patients diagnosed with mild to moderate dementia (range from 12 to 21 MMSE), only 4% could not correctly answer the screening questions and thus were not administered the entire scale. For patients who completed the DQoL, internal consistency reliabilities for subscales were moderate to high. There were no significant differences between patient groups with mild and moderate dementia severity in terms of scale reliability (10) .
QoL-Alzheimer's disease (QoL-AD) has been specifically constructed for self-assessment of QoL in patients suffering from dementia with MMSE . 12 without the intervention of the caregiver. The original instrument foresaw a structured interview composed of 96 items that investigated the characteristics of the patients and their experience of living with dementia; this interview included the evaluation of: the functional condition, basic and complex activities of daily life, mobility, physical comfort, and wellness in social life, ability to interact, aesthetic sense and perception of the quality of life. Validation has reduced the original version to 56 items divided into five domains (aesthetics, positive affections, negative affections, self-esteem, feeling of belonging) and took about 15-20 min to answer (11) . The authors propose the scale as a useful tool for the evaluation of the long-term effects of treatment (see Table 2 ). Although it is keenly recognised that there is no 'gold standard' or superior instrument for assessing QoL, this study has shown that both the QoL-AD and DQoL are useful instruments for capturing QoL from the perspective of the patient with dementia. However, given that the QoL-AD had better rates of completion and internal reliability in this study, the QoL-AD may be the most favourable instrument, particularly for those with more severe cognitive impairment and, to a less extent, functional impairment. Researchers, however, should consider the type of data that they require and for what purpose before making an informed decision on which instrument to employ. It may also be advisable to examine QoL using at least two measurements and to also consider collection of qualitative data as a complementary source of information to ensure the best assessment of QoL and capture of the true perspective of the person with dementia. Items for the QoL-AD were selected to reflect domains of QoL in older adults based on a literature review of QoL in geriatric populations. Face validity and comprehensiveness were ensured by having AD patients, caregivers, older adults without dementia and dementia experts review potential items (see Table 2 ). The final scale is composed of 13 items that measure the domains of physical condition, mood, memory, functional abilities, interpersonal relationships, ability to participate in meaningful activities and financial situation. Response options are four-point multiple choice options (1 5 poor, 4 5 excellent). Scale scores range from 13 to 52, with higher scores indicating greater QoL. Patients and caregivers typically complete the QoL-AD separately. Patients are interviewed and caregivers respond to the QoL-AD items on a questionnaire. Composite scores that combine reports from patients and caregivers are weighted to improve the patient's self-report. The scale takes an average of 10 min to administer to patients, and caregivers take ,10 min to complete the questionnaire (11) . Psychometric properties of the QoL-AD were initially evaluated in a group of 77 AD outpatients and their caregivers (11) . A follow-up study with a larger sample of 177 AD patients was recently published (12) , in which 155 of the 177 patients interviewed were able to complete the QoL-AD. Mean MMSE for patients who did not complete the questionnaire was 4.1 compared with 18.1 for those who did (range 4-29); all patients with MMSE scores above 11 were able to complete the QoL-AD. In addition to greater cognitive impairment, patients who did not complete the questionnaire also showed significantly more impairment in basic and instrumental ADLs. Validity was indicated by low to moderate correlations between QoL scores and the MMSE and reports of instrumental activities of daily living, depression, and engagement in pleasant activities (12) . Validity of patient scores in the second study was indicated by correlations between QoL-AD scores and several measures of domains hypothesised to be associated with QoL: behavioural competence, psychological status, physical function and interpersonal environment. There were stronger associations between caregiver-reported QoL and measures of these other domains (11). The Apparent Affect Rating Scale (AARS) in projects of search is used to assess the QoL in patients institutionalised and affected by moderate to severe dementia. It includes five domains (three belonging to negative symptoms such as anger, anxiety, fear, depression and sadness and two to positive symptoms such as pleasure and interest). This scale requires the assistance of an evaluator trained to interpret the signs and facial expressions of the patient that imply emotions. The period of observation was 5 min. The evaluator should be empathetic and sensitive to nonverbal expressions and should have a good knowledge of the patients, their experiences and the environment in which the evaluation is being carried out (12) (see Table 3 ). The authors of AARS have used different methods to implement the model. Some investigators have interpreted these five domains as defining features of QoL, whereas others have viewed some factors as predictors of QoL and others as indicators of QoL. In fact, some instruments incorporate items on functional and cognitive impairment in the scale, whereas others consider these factors as potential predictors of QoL but not as defining features. Some authors noted that items on cognition and physical functioning in QoL measures were included; there are many problems because these domains inevitably decline with advancing dementia (12). Table 4 ). Several authors have shown that PDQ-39, and particularly its summary index (PDQ-39SI), is a widely used patient-reported clinical trial end point. A basic assumption when Had difficulty doing the leisure activities which you would like to do?
Had difficulty looking after your home, e.g. DIY, housework, cooking?
Had difficulty carrying bags of shopping?
Had problems walking half a mile?
Had problems walking 100 yards?
Had problems getting around the house as easily as you would like?
Had difficulty getting around in public?
Needed someone else to accompany you when you went out?
Felt frightened or worried about falling over in public?
Been confined to the house more than you would like?
Had difficulty washing yourself?
Had difficulty dressing yourself?
Had problems doing up your shoelaces?
Had problems writing clearly?
Had difficulty cutting up your food?
Had difficulty holding a drink without spilling it?
summing items into a total score is that they represent a common variable. The authors have assessed the unidimensionality of the PDQ-39SI using Rasch and confirmatory factor analysis. Both analyses showed model misfit. Adjustment for differential item functioning and disordered response category thresholds did not improve the model fit, and residual analyses showed deviation from unidimensionality. These data indicate multidimensionality and challenge the interpretation and validity of PDQ-39SI scores.
Amyotrophic Lateral Sclerosis Questionnaire
The Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40 and ALSAQ-5) contains 40 questions that measure five inherent areas pertaining to physical and mental health: 'physical mobility' (10 questions), 'daily activity and independence' (10 questions), 'to eat and to drink' (3 questions), 'communication' (7 questions) and 'emotional operation' (10 questions). The questions refer to the condition perceived by the patient during the last 2 weeks; the answers are quantified on a five-point Likert scale. The ALSAQ-5 contains five questions instead, each belonging to one of the five dimensions of the ALSAQ-40 (12) . The lack of treatments for ALS patients and the disease progression indicate the need for palliative therapies that have to be evaluated according to international guidelines. ALSAQ-40 and its shortened form, ALSAQ-5, are widely used ALS patient-focussed disease questionnaires (14) . The purpose of the Avoided situations which involve eating or drinking in public?
Felt embarrassed in public due to having Parkinson's disease?
Felt worried by other people's reaction to you?
Had problems with your close personal relationships?
Lacked support in the ways you need from your spouse or partner?
Lacked support in the ways you need from your family or close friends?
Unexpectedly fallen asleep during the day?
Had problems with your concentration, e.g. when reading or watching TV?
Felt your memory was bad?
Had distressing dreams or hallucinations?
Had difficulty with your speech? I have fallen over whilst walking.
I have stumbled or tripped whilst walking.
I have lost my balance whilst walking.
I have had to concentrate whilst walking.
Walking has tired me out.
I have had pains in my legs whilst walking.
I have found it difficult to go up and down the stairs.
I have found it difficult to stand up.
I have found it difficult to get myself up out of chairs.
I have had difficulty using my arms and hands.
I have found turning and moving in bed difficult.
I have found picking things up difficult.
I have found holding books or newspapers, or turning pages, difficult.
I have had difficulty writing clearly.
I have found it difficult to do jobs around the house.
I have found it difficult to feed myself.
I have had difficulty combing my hair or cleaning my teeth.
I have had difficulty getting dressed.
I have had difficulty washing at the hand basin.
I have had difficulty swallowing.
I have had difficulty eating solid food.
I have found it difficult to drink liquids.
I have found it difficult to participate in conversations.
I have felt that my speech has not been easy to understand.
I have slurred or stuttered whilst speaking.
I have had to talk very slowly.
I have talked less than I used to do. I have felt hopeless about the future.
I have worried that I am a burden to other people.
I have wondered why I keep going.
I have felt angry because of the disease.
I have felt depressed.
I have worried about how the disease will affect me in the future. Climbing several flights of stairs 1 2 3
Climbing one flight of stairs 1 2 3
Bending, kneeling, or stooping 1 2 3
Walking more than a mile 1 2 3
Walking several blocks 1 2 3
Walking one block 1 2 3
Bathing and dressing yourself Have you felt so down in the dumps that nothing could cheer you up? Table 7 ). Several studies have demonstrated that problems other than physical disability, such as mental health problems and bladder and sexual problems, adversely affect the QoL of MS patients. New studies are also needed to further determine the factors that contribute to the reduced QoL of MS patients. Scientific evaluation of such interventions using QoL questionnaires as a measure of patients' perspectives will allow the most useful strategies to be selected. Finally, published results are lacking from randomised clinical trials on the effect of interferon-b on the QoL. A study conducted by the authors has shown a modest effect; the rest were all small and used incomplete designs. A few significant findings might suggest no real effect on the patient's QoL or might be related to the insensitivity of the instrument used. This underlines the need for further studies on the responsiveness of the instruments used (17) .
Conclusion
In the last decade the number of studies on QoL in patients affected by neurological disorders has increased exponentially. Several instruments have been developed, some of which are available in various languages, but the use of QoL as an outcome measure in clinical trials for the disease still has many shortcomings. It lacks a priori specification of how data are analysed and often lacks information about the mode of administration of the questionnaires (direct interview, telephone, self-administration, or other modes) and completeness of compilation. These problems, however, are only partly attributable to the shortcomings of the researcher or a member still not convinced with the current view of enhancing the patient-centred outcomes (19) . Most of the instruments used consist of a set of scales that can in turn be aggregated into a total score and/or a limited number of composite indices. This is particularly important when a tool is used for multidimensional QoL, as the possibility of incurring an error of the first type is increased if we apply the statistical comparisons on individual domains separately, especially if they are re-evaluated over time. The specification of a priori and time domains in which a difference is expected overcomes the problem of multiple comparisons. The results reported in the literature show that, although the development and validation of QoL questionnaires for demyelinating and neurodegenerative diseases have reached a satisfactory level, the consensus on which QoL instruments are preferred in clinical trials and interpretation of results should be the subjects of further research and investigation (20) . In summary, as a result of the achievements of the past two decades, nowadays we have many reliable and valid tools to evaluate the QoL of patients with neurological disorders. The methodology for assessment of QoL continues to develop towards a more precision evaluation through computer adaptive testing, implementation of electronic methods for data collection, integration of health pro le measurement and patient preference weighting, rigour statistical analysis and meaningful interpretation of QoL data. In parallel, we have observed increasing application of QoL instruments as outcome measures in clinical trials and growing interest in their use to aid patient-clinician interaction and policy decision making. The scientific rigour of QOL research will determine the extent to which the resulting data are accepted by clinicians, policymakers and the public.
